Vineet Laboratories growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue−20.8%−34.6%
EBITDA—+3.4%
Net Income—+8.6%
EPS (adj.)—+8.6%
Total Assets+32.0%+2.5%
Total Equity+211.6%+10.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

VINEETLAB₹36.06

Vineet Laboratories Limited

· Pharma & Health
₹ CrorePeersBIOFILCHEMMANGALAMLASAKREBSBIOALPABALPHARMAORTINGLOBENATCAPSUQMcap ₹69.3 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue-20.8-34.6
EBITDA—+3.4
Net Income—+8.6
EPS (adj.)—+8.6
Total Assets+32.0+2.5
Total Equity+211.6+10.6
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.